https://pittplusme.org/study/compass
Compass 2 Hidradenitis Suppurativa Study
STUDY BASICS
Is your Hidradenitis Suppurativa causing painful lumps on your body? If so, you might want to explore the COMPASS 2-HS Study on the Clinago platform! People diagnosed for 1+ years and have at least 5 HS lesions in two or more areas of their body may be eligible. Study participation will last approximately 40 weeks and includes up to 22 visits. Compensation is provided.
STUDY PURPOSE
This study is being done to evaluate the safety and efficacy of BFB759 in participants with moderate to severe hidradenitis suppurativa (HS).
COULD THIS STUDY BE RIGHT FOR YOU?
- Be 18-75 years old.
- Have had a diagnosis of Hidradenitis Suppurativa for at least 1 year.
- Have at least 5 HS lesions in 2 or more areas of their body.
- Be available for 22 visits over 40 weeks.
WHAT PARTICIPANTS CAN EXPECT
During the study, all participants will receive both BFB759 and a placebo (placebo looks like BFB759 but has no active ingredient). Participants will be randomly assigned to receive either BFB759 or the placebo for the first 16 weeks. After this period, they will switch and receive the other treatment for the next 16 weeks. Neither the participants nor the study team will know who is receiving the actual study medication and who is receiving the placebo.
Screening (2-4 weeks) - Participants are screened for eligibility to participate in the trial
Treatment (30 weeks) Bi-weekly visits - Participants receive BFB759 or placebo for 14 weeks, followed by re-randomization for continued treatment through Week 30
Follow-up (6-10 weeks) - Participants are monitored for safety and effectiveness after treatment
IRB: SSU00316252
- Bluefin Biomedicine, Inc. - CL-BFB759-003, A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS) (Pro00089953)
MEET THE RESEARCHER
Joe K. Tung
Joe K. Tung, MD, MBA received his undergraduate degree in Molecular Biophysics and Biochemistry at Yale University and his medical degree at Harvard Medical School. He concurrently obtained his Master of Business Administration from Harvard Business School, graduating in the top 5% as a Baker Scholar. Dr. Tung went on to complete his internal medicine intern year at the Brigham and Women's Hospital and his dermatology residency at the University of Pittsburgh Medical Center.
Dr. Tung won a gold medal representing the United States at the 43rd International Chemistry Olympiad. His basic science and clinical research work have resulted in multiple peer-reviewed articles, reviews, textbook chapters, clinical decision support tools, and presentations at national and international meetings. He serves as a reviewer for research journals, as a consultant for pharmaceutical and biotechnology companies, as a principal investigator for global industry-sponsored clinical trials, and as an advisor for multiple healthcare start-ups. In his spare time, Dr. Tung enjoys traveling, playing golf, rock climbing, visiting museums, and attending live sporting events.